// App-Quantinova.ai

5065 : SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).

Researchers

Presenter

  • Vincenza Conteduca

Principal Investigators

  • Loredana Puca

  • Sheng-Yu Ku

  • Judy Hess

  • Megan Kearney

  • Luisa Fernandez

  • Rohan Bareja

  • Panagiotis J. Vlachostergios

  • Michael Sigouros

  • Juan Miguel Mosquera

  • Andrea Sboner

  • David M. Nanus

  • Olivier Elemento

  • Ryan Dittamore

  • Scott T. Tagawa

  • Himisha Beltran

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Weill Cornell Medicine, New York, NY

  • Epic Sciences, Inc., San Diego, CA

  • BD Biosciences, San Jose, CA

  • Department of Physiology and Biophysics, Institute for Computational Biomedicine, Englander Institute for Precision Medicine, Weill Cornell Medical College, New York, NY

  • Division of Hematology & Medical Oncology, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY

  • Department of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York City, NY

  • Department of Pathology & Laboratory Medicine, Englader Institute for Precision Medicine, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY

  • Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY

  • Sandra and Edward Meyer Cancer Center, New York, NY

  • Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Circulating tumor cells

  • Retinoblastoma protein

  • Tumor protein p53

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved